drugset / Trial / NCT05934097
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase I study of FT596 in combination with two different schedules (standard or alternate) of R-CHOP in subjects with B-cell lymphoma who are previously untreated or have received no more than one prior line of treatment. The study will consist of a dose-escalation stage followed by a dose-expansion stage.
Timeline
- Start
- 2022-12
- Primary completion
- 2026-05
- Completion
- 2039-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 50 mg/m2 | Intravenous |
| Subject | FT596 | Cell therapy | — | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |
| Background | Bendamustine | Small molecule | 90 mg/m2 | Intravenous |
| Background | Prednisone | Other / unclassified | 100 mg | Oral |